OXFORD, UK – 16 December 2015 PsiOxus Therapeutics Ltd. (PsiOxus), the immunooncology company, has initiated a study to assess the safety and efficacy of a therapy combining Merck’s Keytruda® (pembrolizumab)… read more →

OXFORD, UK – 19 May 2015 – PsiOxus Therapeutics Ltd. (PsiOxus), the oncolytic immuno-oncology company, has closed a Series C financing round of £25 million (c$38.5 million) to progress its… read more →

OXFORD, UK – 16 April 2015 PsiOxus Therapeutics Ltd. (PsiOxus), an oncolytic immunoncology company, has announced that it will present data highlighting the progress of its next generation “Antibody Armed… read more →

Phase I Study Results Confirming Intravenous Delivery Profile and Repeated Dosing Leads to Expansion of the Clinical Programme into New Indications OXFORD – 16 April 2015 PsiOxus Therapeutics Ltd. (PsiOxus),… read more →

OXFORD – 13 January 2015 PsiOxus Therapeutics Ltd. (PsiOxus), an Oxford, UK based biotechnology company developing innovative new treatments for cancer, has been granted a positive opinion from the European… read more →

OXFORD – 16 June 2014 PsiOxus Therapeutics Ltd. (PsiOxus), an award winning biotechnology company developing innovative new treatments for cancer, today announced the first dosing of a patient in the… read more →

Studies Identify a Phase II Dose and Demonstrate Best in Class Intravenous Delivery Profile Leading to an Expansion of the Clinical Program to New Indications OXFORD, UK and CHICAGO –… read more →

Phase I Studies to be Presented at 2014 ASCO Annual Meeting OXFORD, UK – 13 APRIL, 2014 – PsiOxus Therapeutics, Ltd. (PsiOxus), an award-winning biotechnology company developing innovative, novel treatments… read more →